Market Focus

Rheumatology and autoimmune disorders:
large, concentrated markets

The market for therapeutics to address rheumatologic diseases and autoimmune disorders has expanded dramatically in the past decade with new treatment options, and continued research and development. It is also a relatively focused market, with an accessible physician audience. Primary assessment and differential diagnosis of these disorders, followed by therapeutic intervention and ongoing care management, is provided or directed by a highly specialized group of 5,200 rheumatologists in the United States.

Rheumatology encompasses a broad set of disorders

While osteoarthritis and rheumatoid arthritis are the most commonly known, there are more than 100 rheumatological disorders. These include:

  • Fibromyalgia
  • Gout
  • Scleroderma
  • Osteoporosis
  • Cellulitis
  • Dermatomyositis
  • Sj√∂gren’s syndrome
  • Marfan syndrome
  • Musculoskeletal Diseases
  • Connective Tissue Diseases
  • Bone Disorders
  • Lupus

Many of these disorders are characterized by challenging diagnoses, chronic or relapsing/remitting symptoms, high rates of recurrence and limited response from current treatments, many of which are relatively expensive and/or include serious adverse events.

Integrating therapeutics and diagnostics to improve patient care

Proprius Pharmaceuticals helps physicians to optimize treatment decisions by bringing together novel therapeutics, pharmacogenetics, diagnostic and prognostic services. As a unique provider of personalized medicine solutions, Proprius is creating a leadership position in the rheumatology and autoimmune disease field with the licensing, development and marketing of pharmaceutical products, and a differentiated approach to commercialization.

Leave a Reply